Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial

Contemporary Clinical Trials Communications

Volumn 2, Issue , 2016, Pages 91-96

  Balaguer, Catalina ^a   Peralta, Alejandro ^a   Ríos, Ángel ^b   Iglesias, Amanda ^c   Valera, Josep Lluís ^a   Noguera, Aina ^a,c,d   Soriano, Joan B ^e   Agustí, Àlvar ^c,d   Sala Llinas, Ernest ^a,c  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Institut d'Investigació Sanitària de Palma   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

COPD; Erythropoietin; Inflammation; Statins; Uric acid

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ERYTHROPOIETIN; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; URIC ACID; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LEUKOCYTE COUNT; LUNG FUNCTION; MALE; NEUTROPHIL COUNT; PILOT STUDY; PLEIOTROPY; PROGNOSIS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SPUTUM ANALYSIS; URIC ACID BLOOD LEVEL;

EID: 84960154283     PISSN: 24518654     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conctc.2015.12.008     Document Type: Review

References (39)

1. J. Vestbo, S.S. Hurd, A.G. Agusti, and et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am. J. Respir. Crit. Care Med. 187 4 2013 347 365
2. M. Miravitlles, J.J. Soler-Cataluna, M. Calle, and et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery Arch. Bronconeumol 48 7 2012 247 257
3. A.G. Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons, and X. Busquets Systemic effects of chronic obstructive pulmonary disease Eur. Respir. J. 21 2 2003 347 360
4. W.Q. Gan, S.F. Man, A. Senthilselvan, and D.D. Sin Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis Thorax 59 7 2004 574 580
5. L.A. Lange, C.S. Carlson, L.A. Hindorff, and et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events JAMA 296 22 2006 2703 2711
6. S.F. Man, J.E. Connett, N.R. Anthonisen, R.A. Wise, D.P. Tashkin, and D.D. Sin C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease Thorax 61 10 2006 849 853
7. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N. Engl. J. Med. 342 12 2000 836 843
8. A. Agusti, L.D. Edwards, S.I. Rennard, and et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype PLoS One 7 5 2012 e37483
9. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 3 1999 230 235
10. C. Arnaud, F. Burger, S. Steffens, and et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins Arterioscler. Thromb. Vasc. Biol. 25 6 2005 1231 1236
11. J.H. Lee, D.S. Lee, E.K. Kim, and et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs Am. J. Respir. Crit. Care Med. 172 8 2005 987 993
12. G.B. Mancini, M. Etminan, B. Zhang, L.E. Levesque, J.M. FitzGerald, and J.M. Brophy Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease J. Am. Coll. Cardiol. 47 12 2006 2554 2560
13. V. Soyseth, P.H. Brekke, P. Smith, and T. Omland Statin use is associated with reduced mortality in COPD Eur. Respir. J. 29 2 2007 279 283
14. R.P. Young, R. Hopkins, and T.E. Eaton Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes Eur. Respir. J. 30 4 2007 616 622
15. R.P. Young, R. Hopkins, and T.E. Eaton Pharmacological actions of statins: potential utility in COPD Eur. Respir. Rev. 18 114 2009 222 232
16. S. Janda, K. Park, J.M. FitzGerald, M. Etminan, and J. Swiston Statins in COPD: a systematic review Chest 136 3 2009 734 743
17. M.T. Wang, Y.W. Lo, C.L. Tsai, and et al. Statin use and risk of COPD exacerbation requiring hospitalization Am. J. Med. 126 7 2013 598 606
18. G.J. Criner, J.E. Connett, S.D. Aaron, and et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD N. Engl. J. Med. 370 23 2014 2201 2210
19. P. Kaczmarek, K. Sladek, W. Skucha, and et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease Pol. Arch. Med. Wewn. 120 1-2 2010 11 17
20. T.M. Lee, M.S. Lin, and N.C. Chang Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin Am. J. Cardiol. 101 4 2008 530 535
21. H. Melbye, D.S. Halvorsen, I. Hartz, and et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001 Respir. Med. 101 12 2007 2541 2549
22. P. Boschetto, B. Beghe, L.M. Fabbri, and C. Ceconi Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice Respirology 17 3 2012 422 431
23. L.M. Fabbri, B. Beghe, and A. Agusti Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines Thorax 66 9 2011 745 747
24. K. Bartziokas, A.I. Papaioannou, S. Loukides, and et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD Eur. Respir. J. 43 1 2014 43 53
25. J. Roca, J. Sanchis, A. gusti-Vidal, and et al. Spirometric reference values from a Mediterranean population Bull. Eur. Physiopathol. Respir. 22 3 1986 217 224
26. S. Laurent, J. Cockcroft, B.L. Van, and et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur. Heart J. 27 21 2006 2588 2605
27. J.D. Maclay, D.A. McAllister, N.L. Mills, and et al. Vascular dysfunction in chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 180 6 2009 513 520
28. C.C. Huang, W.L. Chan, Y.C. Chen, and et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan Clin. Ther. 33 10 2011 1365 1370
29. K. Bartziokas, A.I. Papaioannou, M. Minas, and et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study Pulm. Pharmacol. Ther. 24 5 2011 625 631
30. C.M. Lawes, S. Thornley, R. Young, and et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study Prim. Care Respir. J. 21 1 2012 35 40
31. L. Lahousse, D.W. Loth, G.F. Joos, and et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study Pulm. Pharmacol. Ther. 26 2 2013 212 217
32. A. Ludman, V. Venugopal, D.M. Yellon, and D.J. Hausenloy Statins and cardioprotection-more than just lipid lowering? Pharmacol. Ther. 122 1 2009 30 43
33. R.P. Young, and R.J. Hopkins Possible role of statins in COPD-related pulmonary hypertension Chest 137 5 2010 1250 1251
34. R.G. Barr The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema Proc. Am. Thorac. Soc. 8 6 2011 522 527
35. M.P. van der, A.A. Voors, E. Lipsic, W.H. van Gilst, and D.J. van Veldhuisen Erythropoietin in cardiovascular diseases Eur. Heart J. 25 4 2004 285 291
36. A. Sahinarslan, R. Yalcin, S.A. Kocaman, and et al. The relationship of serum erythropoietin level with coronary collateral grade Can. J. Cardiol. 27 5 2011 589 595
37. W. Xu, Z. Guo, L. Mi, and G. Wang Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion Biomarkers 18 4 2013 343 348
38. N. Werner, S. Kosiol, T. Schiegl, and et al. Circulating endothelial progenitor cells and cardiovascular outcomes N. Engl. J. Med. 353 10 2005 999 1007
39. E. Moutzouri, E.N. Liberopoulos, M. Florentin, G. Liamis, and M.S. Elisaf Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels J. Cardiovasc Pharmacol. Ther. 18 1 2013 13 18